ECPC is doing its best to make sure that each ECPC Annual General Meeting remains the largest gathering of cancer patients in Europe. Last year we welcomed more than 120 ECPC Members, and we hope to increase the number of participants this year. Join us!
An information platform on cancer immunotherapies and immuno-oncology treatments for cancer patients across Europe. The IOP aims to provide patients with all forms of cancer and their caregivers with up-to-date, accessible information about cancer immunotherapy – treatments with use the immune system to fight cancer.
ECPC is establishing a Bladder Cancer Working Group to guarantee that bladder cancer patients and patient organisations will be able to contribute to our bladder cancer activities. Click here and join our Bladder Cancer Working Group!
The Joint Action on Rare Cancers (JARC) aims to integrate and maximize efforts of the European Commission and EU Member States to advance quality of care and research on rare cancers. The Joint Action and the European Reference Networks are crucial game changers for rare cancer patients in Europe.
Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five-year project funded by the European Commission's Innovative Medicines Initiative (IMI) 2 programme to evaluate different ways of assessing clinical patient preferences.
TeamECPC is a group of committed athletes, runners, friends and colleagues who support ECPC by participating on our behalf to competitive and non-competitive sports events. Join our team of runners!